Search results
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
Clinical Trials Arena via Yahoo Finance· 2 days agoUS pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 2 days agoMonday, Merck & Co Inc MRK announced the discontinuation of the vibostolimab and pembrolizumab...
Data-Based Insights About Merck & Co Inc
Stocks Register· 7 days agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $129.66. A look ...
Health Care Roundup: Market Talk
The Wall Street Journal· 4 hours agoLombardi says the company has been working to partner with more suppliers on critical products and to consider internal production. Shares drop...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 3 days ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Stocks Higher After CPI Inflation Report
Investor's Business Daily· 11 hours agoGameStop and AMC tumbled, while Boot Barn and Monday.com are earnings movers.
Bars, music venues left in limbo after South Carolina lawmakers fail to address liquor liability
WYFF 4 Greenville· 1 day agoBar and music owners will now have to wait until next year to hopefully get help from lawmakers in...
Merck’s trial of KEYTRUDA regimen fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 6 days agoMerck has announced that its Phase III KEYNOTE-B21 (ENGOT-en11/GOG-3053) clinical trial of KEYTRUDA...
Merck's endometrial cancer therapy fails trial
AOL· 7 days agoThe drugmaker's Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after surgery. The trial did not meet the main ...
Merck treatment for a type of uterus cancer fails trial
KFGO· 7 days ago(Reuters) - Merck said on Thursday its treatment for a type of uterus cancer did not meet the main...
